4.5 Article

Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy

Journal

EUROPEAN JOURNAL OF HEART FAILURE
Volume 15, Issue 6, Pages 660-670

Publisher

WILEY
DOI: 10.1093/eurjhf/hft019

Keywords

Left atrial volume; Dilated cardiomyopathy; Cardiovascular magnetic resonance; Prognosis

Funding

  1. National Institute for Health Research Cardiovascular Biomedical Research Unit at the Royal Brompton
  2. Harefield NHS Foundation Trust and Imperial College London
  3. CORDA
  4. Rosetrees Trust
  5. British Heart Foundation
  6. National Health and Medical Research Council of Australia
  7. Victor Chang Cardiac Research Institute
  8. St Vincent's Clinic Foundation
  9. MRC [MC_U120085815] Funding Source: UKRI
  10. Medical Research Council [MC_U120085815] Funding Source: researchfish

Ask authors/readers for more resources

Echocardiographic studies have shown that left atrial volume (LAV) predicts adverse outcome in small heart failure (HF) cohorts of mixed aetiology. However, the prognostic value of LAV in non-ischaemic dilated cardiomyopathy (DCM) is unknown. Cardiovascular magnetic resonance (CMR) allows accurate and reproducible measurement of LAV. We sought to determine the long-term prognostic significance of LAV assessed by CMR in DCM. We measured LAV indexed to body surface area (LAVi) in 483 consecutive DCM patients referred for CMR. Patients were prospectively followed up for a primary endpoint of all-cause mortality or cardiac transplantation. During a median follow-up of 5.3 years, 75 patients died and 9 underwent cardiac transplantation. After adjustment for established risk factors, LAVi was an independent predictor of the primary endpoint [hazard ratio (HR) per 10 mL/m(2) 1.08; 95 confidence interval (CI) 1.011.15; P 0.022]. LAVi was also independently associated with the secondary composite endpoints of cardiovascular mortality or cardiac transplantation (HR per 10 mL/m(2) 1.11; 95 CI 1.041.19; P 0.003), and HF death, HF hospitalization, or cardiac transplantation (HR per 10 mL/m(2) 1.11; 95 CI 1.041.18; P 0.001). The optimal LAVi cut-off value for predicting the primary endpoint was 72 mL/m(2). Patients with LAVi 72 mL/m(2) had a three-fold elevated risk of death or transplantation (HR 3.00; 95 CI 1.924.70; P 0.001). LAVi provided incremental prognostic value for the prediction of transplant-free survival (net reclassification improvement 0.17; 95 CI 0.050.29; P 0.002). LAVi is a powerful independent predictor of transplant-free survival and HF outcomes in DCM. Assessment of LAV improves risk stratification in DCM and should be incorporated into routine CMR examination.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available